Ações Danaher Corp. (DHR) — é um bom negócio?

Ações Danaher Corp. (DHR) — é um bom negócio? — InspectStocks

Como ganha dinheiro

Biotechnology: equipment, supplies, and services for biological drug research and manufacturing30%
Life Sciences: research instruments, supplies, and filtration products30%
Diagnostics: instruments, tests, and patient-monitoring products40%

As participações na receita são estimativas para six months ended June 26, 2026, não números de um relatório oficial.

Concorre com

O que vende6

Cytiva bioprocessing products
Filters, resins, liquids, single-use equipment, and services that drugmakers use to develop and manufacture biological medicines.
Pall filtration products
Filters and related equipment that remove contaminants from liquids and gases used in medicine, research, food production, electronics manufacturing, and other industries.
Biacore 8S
A Cytiva instrument that lets researchers test how potential drug molecules interact with their targets.

Mostrar mais 3

SCIEX mass spectrometers
Instruments that identify and measure molecules in samples, used in drug research, clinical testing, and food and environmental testing.
Beckman Coulter clinical testing systems
Laboratory instruments, tests, and software that analyze blood and other body samples to help diagnose and monitor health conditions.
Cepheid GeneXpert tests
Systems and tests that detect genetic material from organisms or diseases, including tests used in hospitals and other care settings.

Quem compra5

Pharmaceutical and biotechnology companies buy research tools, drug-manufacturing equipment, and replacement supplies, often through Danaher's direct sales teams or distributors.
Contract manufacturers and contract development organizations buy equipment, supplies, and services to make medicines for other companies.
Universities, research institutes, and academic laboratories buy instruments and consumables for biological research.

Mostrar mais 2

Hospitals, doctors' offices, and reference laboratories buy diagnostic instruments, tests, and patient-monitoring products.
Industrial customers, including semiconductor, food, energy, and aerospace businesses, buy filtration equipment and replacement filters.

Em que se apoia e o que pode quebrá-lo

Do que o negócio depende

1Some specially specified or regulated components can be obtained from only one supplier or a limited number of suppliers, even though Danaher says no single supplier is material to the company as a whole.
2Danaher sells mainly through its own sales teams and also uses independent distributors; changes in distributor performance or customer purchasing patterns can affect sales.
3Sales depend in part on regulatory clearances and approvals, and on healthcare providers' ability to obtain payment or reimbursement for products and services.

O que pode dar errado

1Competitors and new technologies can take demand or lead to price reductions in Danaher's many product markets.
2Regulatory requirements for medical devices and diagnostic tests, along with changes in healthcare reimbursement and cost controls, can delay sales or affect what customers buy and pay.
3A few large commercial drug manufacturers delayed planned shipments of chromatography resins in the second quarter of 2026, illustrating how customer production schedules and facility readiness can shift biotechnology sales.

Demonstrações financeiras completas →

Sobre a Danaher Corp.

Danaher owns more than 15 operating companies grouped into biotechnology, life sciences, and diagnostics. Their products help researchers study cells and other biological material, help drugmakers make biological medicines, and help healthcare workers test samples and monitor patients. Many products are used up or replaced regularly, so customers buy supplies as well as instruments and services.

Sede: Washington, D.C., United States
Fundada em: 1984
Funcionários: Approximately 60,000 (as of December 31, 2025, high)
Listada em: NYSE
Fim do exercício: December 31

Construído a partir dos próprios documentos de Danaher Corp. entregues à Comissão de Valores Mobiliários dos EUA (SEC). Os números são os divulgados, com o histórico por ação recalculado para a base de ações de hoje. Isto descreve um negócio — não é recomendação de investimento nem sugestão de compra ou venda.

Keep exploring

The themes Danaher is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

Highest-graded in Diagnostics and Research

Graded A or B and worth $2B or more: A first, then the largest.

All 42 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises